Cargando…

Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer

BACKGROUND: The antibody cetuximab, targeting epidermal growth factor receptor (EGFR), is used to treat metastatic colorectal cancer (mCRC). Clinical trials suggest reduced benefit from the combination of cetuximab with oxaliplatin. The aim of this study was to investigate potential negative interac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santoro, Valeria, Jia, Ruochen, Thompson, Hannah, Nijhuis, Anke, Jeffery, Rosemary, Kiakos, Konstantinos, Silver, Andrew R., Hartley, John A., Hochhauser, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864961/ https://www.ncbi.nlm.nih.gov/pubmed/26719345 http://dx.doi.org/10.1093/jnci/djv394

Ejemplares similares

Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin
por: Narvi, Elli, et al.
Publicado: (2018)

The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells
por: Kawakami, Hisato, et al.
Publicado: (2014)

Evidence for different mechanisms of ‘unhooking’ for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples
por: Spanswick, Victoria J, et al.
Publicado: (2012)

Inhibition of GRP78 abrogates radioresistance in oropharyngeal carcinoma cells after EGFR inhibition by cetuximab
por: Sun, Chaonan, et al.
Publicado: (2017)

A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
por: Koo, Dong Hoe, et al.
Publicado: (2007)

Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer
por: Hashimoto, Akari, et al.
Publicado: (2014)

Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation
por: Balin-Gauthier, D, et al.
Publicado: (2008)

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience
por: Adams, R A, et al.
Publicado: (2009)

Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer
por: Zhang, Zhan-Dong, et al.
Publicado: (2014)

RANKL/RANK pathway abrogates cetuximab sensitivity in gastric cancer cells via activation of EGFR and c-Src
por: Zhang, Xiaomeng, et al.
Publicado: (2017)

Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial
por: Garufi, C, et al.
Publicado: (2010)

RANKL/RANK Pathway Abrogates Cetuximab Sensitivity in Gastric Cancer Cells via Activation of EGFR and c-Src [Corrigendum]
Publicado: (2022)

Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer
por: Wei, Li, et al.
Publicado: (2020)

Hepatic arterial infusion but not systemic application of cetuximab in combination with oxaliplatin significantly reduces growth of CC531 colorectal rat liver metastases
por: Sperling, Jens, et al.
Publicado: (2012)

Drug-Induced Reactivation of Apoptosis Abrogates HIV-1 Infection
por: Hanauske-Abel, Hartmut M., et al.
Publicado: (2013)

Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab
por: Ather, Ferdows, et al.
Publicado: (2013)

Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study
por: Kullmann, F, et al.
Publicado: (2009)

Epithelial down‐regulation of the miR‐200 family in fibrostenosing Crohn's disease is associated with features of epithelial to mesenchymal transition
por: Mehta, Shameer J., et al.
Publicado: (2018)

BGP-15 Protects against Oxaliplatin-Induced Skeletal Myopathy and Mitochondrial Reactive Oxygen Species Production in Mice
por: Sorensen, James C., et al.
Publicado: (2017)

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
por: Maughan, Timothy S, et al.
Publicado: (2011)

Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer
por: Pander, Jan, et al.
Publicado: (2015)

Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
por: Folprecht, Gunnar, et al.
Publicado: (2014)

Cetuximab in the management of colorectal cancer
por: Lenz, Heinz-Josef
Publicado: (2007)

Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance
por: Nijhuis, Anke, et al.
Publicado: (2017)

Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study
por: Tarpgaard, Line S., et al.
Publicado: (2014)

Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with RAS wild-type metastatic colorectal cancer
por: Zekri, Jamal, et al.
Publicado: (2022)

Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective
por: Wehler, Thomas C., et al.
Publicado: (2013)

Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapy
por: Sperling, Jens, et al.
Publicado: (2012)

Correction: Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study
Publicado: (2014)

Association between polymorphisms in EGFR and tumor response during cetuximab and oxaliplatin-based combination therapy in metastatic colorectal cancer: Analysis of data from two clinical trials
por: Maeda, Hiromichi, et al.
Publicado: (2019)

Characterization of the Human SNM1A and SNM1B/Apollo DNA Repair Exonucleases
por: Sengerová, Blanka, et al.
Publicado: (2012)

The efficacy of cetuximab in a tissue-engineered three-dimensional in vitro model of colorectal cancer
por: Magdeldin, Tarig, et al.
Publicado: (2014)

FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab
por: Kjersem, Janne B, et al.
Publicado: (2014)

No Survival Benefit from Adding Cetuximab or Panitumumab to Oxaliplatin-Based Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer in KRAS Wild Type Patients: A Meta-Analysis
por: Zhou, Si-wei, et al.
Publicado: (2012)

Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer
por: Bai, Liangliang, et al.
Publicado: (2019)

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
por: Lordick, F, et al.
Publicado: (2010)

Erratum to: Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective
por: Wehler, Thomas C., et al.
Publicado: (2013)

TNIK inhibition abrogates colorectal cancer stemness
por: Masuda, Mari, et al.
Publicado: (2016)

Evolving role of cetuximab in the treatment of colorectal cancer
por: Schuch, Gunter, et al.
Publicado: (2009)

PRSS contributes to cetuximab resistance in colorectal cancer
por: Tan, Zhaoli, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qo27fcadprt1nc2gip1lh7f6mc